Targeted Dendrimer-Minocycline Nanotherapy for Brain Disorders

  • Unique Paper ID: 207461
  • Volume: 13
  • Issue: 3
  • PageNo: 1334-1341
  • Abstract:
  • Brain disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, and glioblastoma remain challenging to treat because of the limited ability of therapeutic agents to cross the blood-brain barrier (BBB) and achieve targeted drug delivery. Dendrimer-based nanotechnology has emerged as a promising strategy to overcome these limitations by enabling site-specific drug delivery with improved bioavailability and reduced systemic toxicity. Among various therapeutic agents, minocycline, a second-generation tetracycline antibiotic, has demonstrated significant neuroprotective, anti-inflammatory, antioxidant, and anti-apoptotic properties. However, its clinical application is constrained by poor brain targeting and dose-related adverse effects. Targeted dendrimer-minocycline nanotherapy offers an innovative approach by conjugating minocycline with dendrimer nanoparticles, facilitating selective accumulation in activated microglia and inflamed brain tissues. In our study, we developed a dendrimer–minocycline conjugate designed to improve the targeted delivery of minocycline to injured CNS tissue. This rationally designed dendrimer–minocycline nanomedicine integrates the pharmacological potential of minocycline with the neuroinflammation-targeting properties of hydroxyl PAMAM dendrimers.

Copyright & License

Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BibTeX

@article{207461,
        author = {Dr. Devinder Maheshwari and Sukhdeep Singh},
        title = {Targeted Dendrimer-Minocycline Nanotherapy for Brain Disorders},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {3},
        pages = {1334-1341},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=207461},
        abstract = {Brain disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, and glioblastoma remain challenging to treat because of the limited ability of therapeutic agents to cross the blood-brain barrier (BBB) and achieve targeted drug delivery. Dendrimer-based nanotechnology has emerged as a promising strategy to overcome these limitations by enabling site-specific drug delivery with improved bioavailability and reduced systemic toxicity. Among various therapeutic agents, minocycline, a second-generation tetracycline antibiotic, has demonstrated significant neuroprotective, anti-inflammatory, antioxidant, and anti-apoptotic properties. However, its clinical application is constrained by poor brain targeting and dose-related adverse effects. Targeted dendrimer-minocycline nanotherapy offers an innovative approach by conjugating minocycline with dendrimer nanoparticles, facilitating selective accumulation in activated microglia and inflamed brain tissues. In our study, we developed a dendrimer–minocycline conjugate designed to improve the targeted delivery of minocycline to injured CNS tissue. This rationally designed dendrimer–minocycline nanomedicine integrates the pharmacological potential of minocycline with the neuroinflammation-targeting properties of hydroxyl PAMAM dendrimers.},
        keywords = {},
        month = {August},
        }

Cite This Article

Maheshwari, D. D., & Singh, S. (2026). Targeted Dendrimer-Minocycline Nanotherapy for Brain Disorders. International Journal of Innovative Research in Technology (IJIRT), 13(3), 1334–1341.

Related Articles